Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Ammonium bicarbonate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Ammonium bicarbonate
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 4 · Randomised trials: 1 · 1965–2026
Showing the 50 most relevant studies, sorted by most relevant.
Mahmoud Hussein AAA, Shiddo D, Alla Osman KD, et al.
2025
Winter IP, Sarac P, Wilson PB
2026
- Gastrointestinal Diseases
- Sodium Bicarbonate
- Dietary Supplements
Nipon Ngupis, Bancha Satirapoj, Theerasak Tangwonglert, et al.
Scientific Reports, 2025
- Bicarbonates
- Sodium Bicarbonate
- Transforming Growth Factor beta
F. Mani, M. Peruzzini, P. Stoppioni
Green Chemistry, 2006
J.M. Bremner, D.R. Keeney
Analytica Chimica Acta, 1965
Meng Li, Biao Liu, Shili Zheng, et al.
Journal of Cleaner Production, 2017
Autumn N. Harris, Mythri Skankar, Michal Melanmed, et al.
Advances in kidney disease and health, 2023
Das S, Agarwal V, Paul TV, et al.
2026
Acid-base homeostasis is maintained by renal and respiratory systems. The inability of the renal tubules to excrete acids or retain bicarbonate in adequate amounts leads to renal tubular acidosis (RTA). These disorders are characterised by the presence of normal anion gap metabolic acidosis with hyperchloremia. Both distal RTA (type 1) and proximal RTA (type 2) can occur due to a primary/inherited defect in the renal tubule or may arise due to some secondary/acquired causes. Urinary acidification defect defines type 1 RTA, while type 2 RTA is characterised by defective bicarbonate handling in the proximal tubule. Type 3 RTA includes features of both type 1 and type 2 RTA, whereas type 4 RTA is characterised by the presence of hyperkalaemia with normal anion gap metabolic acidosis. In this review article, we describe the various types of RTA and its pathophysiology along with a systematic and practical approach to a suspected case of RTA and its management.
Abstract licence: CC BY-NC-SA
N. Wen, M. H. Brooker
The Journal of Physical Chemistry, 1995
Caibin Wu, Bensheng Li, Chengfang Yuan, et al.
Waste management, 2019
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
experimental
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Ammonium bicarbonate
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72